FTC Sees Reduction In “Reverse” Payments From Brand To Generic Firms
Executive Summary
"Reverse" payments from brand to generic companies in exchange for not launching a generic seem to be disappearing, the Federal Trade Commission notes
You may also be interested in...
Patent Suit Settlements On The Rise After Failure Of FTC Challenges – Barr
Settlements of patent litigation cases have become increasingly common because the Federal Trade Commission has been unsuccessful in challenging the validity of some agreements, Barr CEO Bruce Downey said Jan. 5 at the Morgan Stanley Pharmaceutical CEOs Unplugged conference in New York
Patent Suit Settlements On The Rise After Failure Of FTC Challenges – Barr
Settlements of patent litigation cases have become increasingly common because the Federal Trade Commission has been unsuccessful in challenging the validity of some agreements, Barr CEO Bruce Downey said Jan. 5 at the Morgan Stanley Pharmaceutical CEOs Unplugged conference in New York
FTC Notification Requirement For Brand/Generic Deals Begins
Generic and brand drug firms entering into patent settlements must notify the Federal Trade Commission and the Department of Justice beginning Jan. 7